OncoMatch/Clinical Trials/NCT06641908
Anti-GD2 ADC M3554 in Advanced Solid Tumors
Official title: A Phase 1, Two-Part, Multicenter, Open-Label First in Human Study of Anti-GD2 Antibody Drug Conjugate M3554 in Participants With Advanced Solid Tumors
Is NCT06641908 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies M3554 for advanced solid tumor.
Treatment: M3554 — The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Glioblastoma
Sarcoma
Biomarker criteria
Required: IDH1 wild-type
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anthracycline-containing systemic therapy — locally advanced/metastatic STS
progressed after at least one prior line of anthracycline-containing systemic therapy for the locally advanced/metastatic setting
Must have received: systemic therapy — glioblastoma
glioblastoma, IDH-wildtype, who have progressed after ONLY one prior line of therapy (including radiotherapy +/- temozolomide, depending on the O^6-methylguanine-DNA methyltransferase [MGMT] status)
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana-Farber Cancer Institute · Boston, Massachusetts
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - Memorial Sloan Kettering Cancer Center (CC)- Westc · New York, New York
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06641908 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received anthracycline-containing systemic therapy and systemic therapy.
Does this trial require IDH1?
Yes, IDH1 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages